Your browser doesn't support javascript.
loading
A general computational design strategy for stabilizing viral class I fusion proteins.
Gonzalez, Karen J; Huang, Jiachen; Criado, Miria F; Banerjee, Avik; Tompkins, Stephen M; Mousa, Jarrod J; Strauch, Eva-Maria.
Afiliação
  • Gonzalez KJ; Institute of Bioinformatics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, 30602, USA.
  • Huang J; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA.
  • Criado MF; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA.
  • Banerjee A; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA.
  • Tompkins SM; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA.
  • Mousa JJ; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA.
  • Strauch EM; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA.
Nat Commun ; 15(1): 1335, 2024 Feb 13.
Article em En | MEDLINE | ID: mdl-38351001
ABSTRACT
Many pathogenic viruses rely on class I fusion proteins to fuse their viral membrane with the host cell membrane. To drive the fusion process, class I fusion proteins undergo an irreversible conformational change from a metastable prefusion state to an energetically more stable postfusion state. Mounting evidence underscores that antibodies targeting the prefusion conformation are the most potent, making it a compelling vaccine candidate. Here, we establish a computational design protocol that stabilizes the prefusion state while destabilizing the postfusion conformation. With this protocol, we stabilize the fusion proteins of the RSV, hMPV, and SARS-CoV-2 viruses, testing fewer than a handful of designs. The solved structures of these designed proteins from all three viruses evidence the atomic accuracy of our approach. Furthermore, the humoral response of the redesigned RSV F protein compares to that of the recently approved vaccine in a mouse model. While the parallel design of two conformations allows the identification of energetically sub-optimal positions for one conformation, our protocol also reveals diverse molecular strategies for stabilization. Given the clinical significance of viruses using class I fusion proteins, our algorithm can substantially contribute to vaccine development by reducing the time and resources needed to optimize these immunogens.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Proteínas Virais de Fusão Tipo de estudo: Guideline Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Proteínas Virais de Fusão Tipo de estudo: Guideline Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article